FOLLOW US

Kestra Medical Technologies Ltd. made a high-voltage entrance into the public market on Thursday, launching an electrifying $202 million initial public offering (IPO) that exceeded expectations. The Kirkland, Washington-based company, a pioneer in wearable defibrillator technology, priced its upsized IPO at $17 per share—leaping past its marketed range of $14 to $16. The strong demand led Kestra to increase its initial share offering from 10 million to nearly 11.9 million shares.

With this bold move, Kestra's valuation surged to an estimated $810 million, based on its 47.65 million outstanding shares disclosed in regulatory filings. Shares began trading on Nasdaq under the ticker "KMTS", signaling a new chapter for the company.

Life-Saving Innovation Sparks Investor Excitement

Kestra is reshaping the future of cardiac care with its non-invasive, wearable defibrillator, designed for patients at heightened risk of sudden cardiac arrest. The device, discreetly worn under regular clothing, continuously monitors heart rhythms and delivers lifesaving defibrillation shocks when needed.

More than 550 hospitals across the U.S. prescribe the system, and over 17,000 patients have relied on it for protection, according to Kestra’s filing with the U.S. Securities and Exchange Commission (SEC).

Fueling Growth with IPO Proceeds

With the IPO war chest now secured, Kestra aims to accelerate its commercial expansion, investing in salesforce growth, clinical care specialists, and research & development. While the company has yet to turn a profit, its revenue trajectory is surging.

For the six months ending Oct. 31, Kestra reported a staggering revenue growth of nearly 300%, jumping from $9.5 million to $27.5 million year-over-year—an indicator of its rapidly expanding market footprint.

Bain Capital’s Hold and the IPO Windfall

Private equity powerhouse Bain Capital, Kestra’s majority stakeholder, saw its ownership shrink from 67% to 53% post-IPO. Meanwhile, underwriters secured an over-allotment option, allowing them to sell an additional 1.78 million shares, potentially pushing total IPO proceeds to $232.3 million.

Power Players Behind the Deal

Kestra’s IPO was powered by financial heavyweights, with BofA Securities Inc., Goldman Sachs & Co. LLC, and Piper Sandler & Co. serving as lead underwriters.

Legal counsel played a crucial role, with Kirkland & Ellis LLP, led by partners Sophia Hudson and Christie W.S. Mok, guiding Kestra. Meanwhile, the underwriters were represented by Allen Overy Shearman Sterling LLP, with partner Ilir Mujalovic at the helm.

A Thrilling New Chapter for Kestra

With the IPO launch generating strong investor enthusiasm, Kestra is now armed with fresh capital to scale its cutting-edge cardiac solutions. As it races ahead in the high-stakes medical tech arena, all eyes are on Kestra to see if its trajectory continues to surge—just like the life-saving shocks delivered by its revolutionary device.